John McCaffrey

5.1k total citations
64 papers, 1.4k citations indexed

About

John McCaffrey is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, John McCaffrey has authored 64 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in John McCaffrey's work include Prostate Cancer Treatment and Research (14 papers), Cancer Treatment and Pharmacology (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). John McCaffrey is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Cancer Treatment and Pharmacology (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). John McCaffrey collaborates with scholars based in Ireland, United States and United Kingdom. John McCaffrey's co-authors include Anthony Delaney, Simon Finfer, Malcolm Kell, Fiona Furlong, Amanda McCann, Luke Gubbins, Karolina Weiner‐Gorzel, Matthew Ho, Shiva Sharma and Riona Tully and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

John McCaffrey

60 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John McCaffrey Ireland 15 575 393 366 243 195 64 1.4k
David Rubin United States 22 810 1.4× 224 0.6× 416 1.1× 194 0.8× 145 0.7× 56 1.7k
Yao‐Li Chen Taiwan 23 277 0.5× 315 0.8× 419 1.1× 232 1.0× 330 1.7× 101 1.5k
Wenyang Jiang China 22 480 0.8× 294 0.7× 1.0k 2.8× 550 2.3× 137 0.7× 50 2.0k
John Wang United States 22 292 0.5× 314 0.8× 519 1.4× 221 0.9× 287 1.5× 81 1.4k
Zhonghua Wang China 22 334 0.6× 497 1.3× 397 1.1× 351 1.4× 69 0.4× 81 1.2k
Maheswari Senthil United States 22 320 0.6× 400 1.0× 266 0.7× 251 1.0× 128 0.7× 92 1.3k
F. W. Schildberg Germany 21 449 0.8× 712 1.8× 712 1.9× 186 0.8× 272 1.4× 45 2.5k
Lei Gao China 26 363 0.6× 294 0.7× 770 2.1× 414 1.7× 190 1.0× 110 1.8k
Dustin M. Walters United States 19 417 0.7× 603 1.5× 160 0.4× 167 0.7× 138 0.7× 44 1.4k
Takashi Miyamoto Japan 22 382 0.7× 96 0.2× 539 1.5× 90 0.4× 326 1.7× 116 1.7k

Countries citing papers authored by John McCaffrey

Since Specialization
Citations

This map shows the geographic impact of John McCaffrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John McCaffrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John McCaffrey more than expected).

Fields of papers citing papers by John McCaffrey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John McCaffrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John McCaffrey. The network helps show where John McCaffrey may publish in the future.

Co-authorship network of co-authors of John McCaffrey

This figure shows the co-authorship network connecting the top 25 collaborators of John McCaffrey. A scholar is included among the top collaborators of John McCaffrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John McCaffrey. John McCaffrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations
2.
McCaffrey, John, et al.. (2023). DPD deficiency in an Irish oncology centre: Prevalence and clinical implications. Journal of Oncology Pharmacy Practice. 30(6). 977–982. 2 indexed citations
3.
Kelly, Michael E., Edward S. Murphy, Jarlath Bolger, et al.. (2021). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era. Irish Journal of Medical Science (1971 -). 190(4). 1373–1377. 3 indexed citations
4.
McCaffrey, John, et al.. (2020). An Unusual Case of Gastrointestinal Bleeding in Metastatic Renal Cell Carcinoma. Case Reports in Oncology. 13(2). 738–741. 1 indexed citations
5.
Conroy, Michael, Megan Greally, Owen J. MacEneaney, Conor O’Keane, & John McCaffrey. (2018). Sarcomatoid Carcinoma of the Prostate Presenting in a 44 Year Old. PubMed. 111(9). 825–825. 2 indexed citations
6.
Keane, Fergus, et al.. (2018). Prostate-specific membrane antigen (PSMA) PET-CT imaging in the investigation and management of biochemical recurrence in prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 208–208. 3 indexed citations
7.
Kelly, Catherine M., John McCaffrey, Michelle L. Smith, et al.. (2017). Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland. Annals of Oncology. 28. v643–v644. 6 indexed citations
8.
Kelly, Catherine M., et al.. (2016). Accrual to Cancer Clinical Trial.. PubMed. 109(7). 436–436. 1 indexed citations
9.
Sznol, Mario, Pier Francesco Ferrucci, David Hogg, et al.. (2016). Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL). Annals of Oncology. 27. vi385–vi385. 2 indexed citations
10.
Kelly, Deirdre, Eileen M. McMahon, Eoin C. Kavanagh, et al.. (2016). Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review. Radiology Case Reports. 11(3). 251–254. 8 indexed citations
11.
O’Neil, Bert H., Séamus O’Reilly, Samer S. Kasbari, et al.. (2016). A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy. Annals of Oncology. 27. vi153–vi153. 4 indexed citations
12.
O’Neill, Brenda, Bronagh Blackwood, Evie Gardner, et al.. (2016). Effectiveness of an exercise programme on physical function in patients discharged from hospital following critical illness: a randomised controlled trial (the REVIVE trial). Thorax. 72(7). 594.1–595. 43 indexed citations
13.
Gubbins, Luke, Shiva Sharma, Riona Tully, et al.. (2015). The fate of chemoresistance in triple negative breast cancer (TNBC). PubMed. 3. 257–275. 306 indexed citations
14.
Fennell, Dean A., Clíona McDowell, Sara Busacca, et al.. (2012). Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 7(9). 1466–1470. 39 indexed citations
15.
Cooke, Alexandra B., et al.. (2011). Survey of echocardiography provision and practice in ICUs in the United Kingdom. Critical Care. 15(S1).
16.
McCaffrey, John, et al.. (2011). Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Medicine. 38(3). 359–367. 105 indexed citations
17.
Delaney, Anthony, Celia Bradford, John McCaffrey, Sean M. Bagshaw, & Richard Lee. (2008). Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. International Journal of Cardiology. 138(3). 281–289. 59 indexed citations
18.
Gallagher, David, Austin G. Duffy, & John McCaffrey. (2007). Wilms’ tumour in adults: a case report and review of the literature. Irish Journal of Medical Science (1971 -). 176(1). 49–51. 4 indexed citations
19.
Pfister, David G., John McCaffrey, Gary K. Schwartz, et al.. (2002). A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Investigational New Drugs. 20(1). 123–127. 20 indexed citations
20.
Berg, William J., John McCaffrey, Lawrence H. Schwartz, et al.. (1998). A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Investigational New Drugs. 16(4). 337–340. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Rubin Breakdown of academic impact, for papers by Yao‐Li Chen Breakdown of academic impact, for papers by Wenyang Jiang Breakdown of academic impact, for papers by John Wang Breakdown of academic impact, for papers by Zhonghua Wang Breakdown of academic impact, for papers by Maheswari Senthil Breakdown of academic impact, for papers by F. W. Schildberg Breakdown of academic impact, for papers by Lei Gao Breakdown of academic impact, for papers by Dustin M. Walters Breakdown of academic impact, for papers by Takashi Miyamoto
Rankless by CCL
2026